Projects

Senior Research Fellow
RNDr. Lucia Kováčiková, PhD.

International

Finished
  • Targeting Molecular Pathways of Glucolipotoxicity by a Novel Carboxymethylated Mercaptotriazinoindole Inhibitor of Aldo-Keto Reductase AKR1B1 In Diabetes, Inflammation and Age-related Neurodegeneration
    Program: Bilateral - other
    Duration: 1. 5. 2016 – 30. 4. 2019

National

Current
  • Ligand induced modulation of calcium pump SERCA – study of mechanism and design of new compounds
    Program: VEGA
    Duration: 1. 1. 2022 – 31. 12. 2026
  • Aldo-keto reductase inhibitors in the personalized therapy of several types of cancer
    Program: VEGA
    Duration: 1. 1. 2022 – 31. 12. 2025
  • Development of multifunctional aldose reductase inhibitors based on triazinoindoles: Optimization of their biological activity, selectivity, bioavailability and antioxidant properties.
    Program: VEGA
    Duration: 1. 1. 2022 – 31. 12. 2025
  • Multi-target approach to diverse molecular mechanisms of diabetic complications and other glucose toxicity related diseases
    Program: SRDA
    Duration: 1. 8. 2021 – 30. 6. 2025
  • Gut microbiota and diabetic peripheral neuropathy: effect of cemtirestat in rat models of diabetes
    Program: SRDA
    Duration: 1. 7. 2020 – 30. 6. 2024
Finished
  • Development of products by modification of natural compounds and study of their multi-modal effects onCOVID-19 disease
    Program:
    Duration: 1. 7. 2021 – 30. 6. 2023
  • Indole-1-acetic acid derivatives as aldose reductase inhibitors: structure – activity relationships
    Program: VEGA
    Duration: 1. 1. 2018 – 31. 12. 2021
  • Pharmacological intervention in glucose-toxicity in type 2 diabetes
    Program: SRDA
    Duration: 1. 7. 2016 – 30. 6. 2020
  • Multi-target paradigm for innovative ligand identification in the drug discovery process
    Program:
    Duration: 18. 4. 2016 – 17. 4. 2020
Employees